Stent fracture after transjugular intrahepatic portosystemic shunt placement using the bare metal stent/stent-graft combination technique

BACKGROUND A transjugular intrahepatic portosystemic shunt(TIPS)is widely placed to treat portal hypertension.Because the Viatorr®stent(W.L.Gore and Associates,Flagstaff,AZ,United States)is not available in all hospitals in China,the bare metal stent(BMS)/stent-graft combination technique is still popular for TIPS construction.Stent fracture is a complication after TIPS placement using this technique,with limited available literature focusing on it.AIM To assess the incidence of stent fracture after TIPS placement using the BMS/stent-graft combination technique and to identify the risk factors for stent fracture.We proposed technique modifications to improve the clinical results of TIPS placement with the BMS/stent-graft combination technique.METHODS We retrospectively analyzed the computed tomography(CT)data of all patients with portal hypertension who underwent the TIPS procedure between June 2011 and December 2021 in a single center.Patients implanted with the BMS/stent graft and had follow-up imaging data available were included.We identified patients with stent fracture and analyzed their characteristics.Multivariable logistic regression was applied to identify the potential predictors of stent fracture.RESULTS Of the 68 included patients,stent fracture occurred in seven(10.3%)patients.Based on CT images,the stent fractures were categorized into three types.Our study consisted of four(57.1%)type I fractures,one(14.3%)type II fracture,one(14.3%)type IIIa fracture,and one(14.3%)type IIIb fracture.After adjusting for covariates,multivariable logistic regression revealed that the risk factors for stent fracture were the implantation of a greater number of stents[adjusted odds ratio(aOR)=22.2,95%confidence interval(CI):1.2-415.4,P=0.038]and a larger proximal sagittal stent bending angle(aOR=1.1,95%CI:1.0-1.3,P=0.020).CONCLUSION Stent fracture occurred in approximately 10%of patients with portal hypertension who underwent TIPS with the BMS/stent-graft combination technique.The number of implanted stents and stent bending angle at the inferior vena cava end were predictors of stent fracture,which suggests that the incidence of stent fracture could potentially be reduced by procedural modifications.

Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions

sTo 与大冠的 vessels.MethodsFrom 2004年4月为病人与赤裸金属的 stents ( BMS )相比评估 drug-eluting stents ( DES )的长期的安全和有效性到2006年10月， 2407 个连续病人经历 de novo 损害有比大或等于在在中国北京的 Fu Wai 医院的 3.5 公里的参考容器直径的经皮的冠的干预，有希望地被注册进这研究。我们包括死亡，心肌的梗塞(MI ) ，血栓，目标损害 revascularization (TLR ) ，目标容器 revascularization (TVR ) ，和主要不利心脏的事件获得了 9 年的临床的结果(向，死亡， MI，和 TVR 合成) 。我们执行了艇长比例危险的模型在倾向 match.ResultsAfter 倾向得分以后估计所有结果措施的相对风险， 514 个对待 DES 的病人被匹配到 514 个对待 BMS 的病人。与 BMS 对待的病人与 TLR 的更高的风险被联系(HR：2.55， 95%CI：1.520-4.277， P = 0.0004 ) 并且 TVR (HR：1.889， 95%CI：1.185-3.011， P = 0.0075 ) ，但是 death/MI 和向的率不是统计上不同的。所有学术研究协会定义 stent 血栓在 9 年在二 groups.ConclusionsDuring 是可比较的整个九年的长期的后续，在有大冠的动脉的病人的 DES 的使用仍然在 TLR 和 TVR 的风险与重要减小被联系。

Which Offers the Best? Stent Graft or Bare Metal Stent for Endovascular Treatment of Aortoiliac Disease

Background: In the present study, it was aimed to compare the stent grafts and bare-metal stents in terms of post-procedural patency, clinical recovery and complications in the subjects with symptomatic aorto-iliac arterial disease. Methods: A total of 79 subjects with symptomatic aorto-iliac arterial disease treated with endovascular methods were included in the present study. Forty three subjects received self-expendable bare metal stent (ev3 Protégé stent system, Endovascular Inc., Plymouth, Minnesota, USA) and 36 subjects received PTFE-covered stent graft (Fluency Plus Stent Graft, Bard Peripheral Vascular, Tempe, Arizona). The subjects were compared after and at Months 1, 6, and 12 following the procedure in terms of Rutherford’s classification, ankle-arm index (AAI), patency rates, and complications. Results: The subjects receiving bare metal stent and stent graft for aorto-iliac arterial disease were followed for averagely 15 months. For the subjects receiving bare metal stent, primary patency rates at months 1, 6, and 12 were 98%, 81%, and 70%, respectively, while secondary patency rate at month 12 was found to be 84%. For the group of stent graft, primary patency rates were found as 97%, 97%, and 92%, respectively and secondary patency rate at month 12 was found to be 94%. Stent grafts were applied at the same time in 2 patients who had metal bare metal because the rupture occurred during the procedure. In the comparison between two groups, the group of stent graft was found to be statistically superior to the other in terms of patency, clinical and post-procedural complications. Conclusion: In conclusion, it was found that the stent grafts were superior to the bare metal stents in terms of patency and complication rates in the subjects with symptomatic aortoiliac disease.

Twelve Months Clinical Outcomes after Percutaneous Coronary Intervention with Bare Metal Stents in Unselected Real-Life Patients with Coronary Artery Disease: Results from FLEXUS Study

Background: Though drug-eluting stent is widely used during coronary angioplasty, still there are conditions in which bare metal stents possess a priority role. Objectives: The aim of FLEXUS study is to investigate the safety and efficacy of Flexinnium stent in unselected real-life patients. Methods: The FLEXUS is a single-centric, observational, non-randomized, retrospective study performed from January to August 2014 in 216 patients who received Flexinnium stent. The end-point of study included device-oriented and patient-oriented clinical outcomes as per Academic Research Consortium consensus. These end-points were observed at in-hospital stay and 12-month follow-up. Results: Of 216 patients, 174 (80.6%) patients were male;there were 76 (35.2%) and 84 (38.9%) patients of diabetes and hypertension, respectively. Type B2 and C lesions accounted for 27 (11.3%) and 122 (50.8%), respectively. A total of 241 Flexinnium stents were implanted with an average diameter and length of 2.7 ± 0.2 mm and 21.6 ± 8.0 mm, respectively. The cumulative device-oriented composite at 12-month follow-up included 2.31% cardiac death, 1.39% myocardial infarction (MI) attributed to the target vessel, and 3.70% target lesion revascularization (TLR). Conclusion: FLEXUS study gives an idea about favorable safety and efficacy of the Flexinnium in unselected real-life patients with both simple and complex coronary lesions.

覆膜支架与裸支架在主髂动脉闭塞症中的疗效分析

主髂动脉闭塞症(AIOD)是以盆腔缺血和/或下肢缺血为主要表现的疾病,其发病率、就诊率呈逐年上升趋势,已成为血管外科的常见疾病。随着介入材料不断发展和手术医师介入技术的不断提高,腔内治疗凭借其创伤小、操作方便、效果明确、周期短、病死率低、术后并发症少等优点,逐步成为临床医师治疗AIOD的首选治疗方式。目前关于裸支架和覆膜支架在AIOD患者中的疗效研究较少,本综述旨在探讨覆膜支架与裸支架在AIOD中的疗效,以期为AIOD患者的腔内治疗提供参考。

A Novel High Nitrogen Nickel-free Coronary Stents System: Evaluation in a Porcine Model

Objective To study the safety of the novel high nitrogen nickel-free austenitic stainless steel bare metal stents （BMS） in a recognized porcine coronary model and to select a better grid structure of it. Methods Three types of stents were randomly implanted in different coronary arteries of the same pig： 316L stainless steel BMS （316L-BMS） （n=12）, novel high nitrogen nickel-free stents Grid A （NF-A-BMS） （n=12） and novel high nitrogen nickel-free stents Grid B （NF-B-BMS） （n=12）. In total, eighteen animals underwent successful random placement of 36 oversized stents in the coronary arteries. Coronary angiography was performed after 36 d of stents implantation. Nine animals were respectively sacrificed after 14 d and 36 d for histomorphologic analysis. 〈br〉 Results Quantitative coronary angiography （QCA） showed similar luminal loss （LL） in the three groups：（0.21±0.17） mm for 316L-BMS, （0.16±0.12） mm for NF-A-BMS, （0.24±0.15） mm for NF-B-BMS （P=0.05）. Histomorphomeric analysis after 15 d and 36 d revealed that there was also no significant difference among the three groups in neointimal area （NA） with similar injury scores respectively. High magnification histomorphologic examination showed similar inflammation scores in the three groups, but NF-A-BMS group had poorer endothelialization scores compared with NF-B-BMS group, 2.00±0.63 vs. 2.83±0.41 （P=0.015） at 15 d, which also could be proved by the scanning electron microscope. However, the difference could not been observed at 36 d. Conclusion The novel NF-BMS showed similar safety as 316L-BMS during the short-term study. NF-B-BMS had better endothelialization than NF-A-BMS and this may owe to the specific strut units.

Coronary stenting:A matter of revascularization

In the last few decades, the recommended treatment for coronary artery disease has been dramatically improved by percutaneous coronary intervention(PCI) and the use of balloon catheters, bare metal stents(BMSs), and drug-eluting stents(DESs). Catheter balloons were burdened by acute vessel occlusion or target-lesion restenosis. BMSs greatly reduced those problems holding up the vessel structure, but showed high rates of instent re-stenosis, which is characterized by neo-intimal hyperplasia and vessel remodeling leading to a renarrowing of the vessel diameter. This challenge was overtaken by first-generation DESs, which reduced restenosis rates to nearly 5%, but demonstrated delayed arterial healing and risk for late in-stent thrombosis, with inflammatory cells playing a pivotal role. Finally, new-generation DESs, characterized by innovations in design, metal composition, surface polymers, and antiproliferative drugs, finally reduced the risk for stent thrombosis and greatly improved revascularization outcomes. New advances include bioresorbable stents potentially changing the future of revascularization techniques as the concept bases upon the degradation of the stent scaffold to inert particles after its function expired, thus theoretically eliminating risks linked with both stent thrombosis and re-stenosis. Talking about DESs also dictates to consider dual antiplatelet therapy(DAPT), which is a fundamental moment in view of the good outcome duration, but also deals with bleeding complications. The better management of patients undergoing PCI should include the use of DESs and a DAPT finely tailored in consideration of the potentially developing bleeding risk in accordance with the indications from last updated guidelines.

Major clinical and angiographic outcome of drug eluting stents in native ostial coronary artery disease

Objectives: The study was designed to evaluate the efficacy and safety of drug eluting stents (DESs) in aorto-ostial (A-O) coronary artery lesions, in terms of early and late restenosis rate;including clinical assessment, non-invasive stress testing and angiographic follow-up. Also, the study was aimed to compare the results of implantation of drug eluting stents (DES) to that of bare metal stents (BMS) in aortoostial lesions done over a previous 5 years in Royal Brompton Hospital. Background: The safety and effectiveness of DESs for the treatment of aortoostial lesions. Methods: We included 161 consecutive patients with symptoms subjective of angina pectoris or objective evidence of myocardial ischemia;who underwent percutaneous coronary interventions (PCI) in coronary ostial lesions using DES. The patients were divided into two groups based on the site of ostial lesion. The control group consisted of 125 consecutive patients who underwent percutaneous coronary intervention for ostial lesions using bare metal stents (BMS) implantation in the period immediately before the introduction of DES. The incidence of major adverse cardiac events (MACE), including death or Q-wave myocardial infarction (MI), need for repeated revascularization procedure CABG or angioplasty, were recorded in-hospital and at twelve months ± 3 months. Follow-up angiography was only performed in case of recurrent symptoms subjective of myocardial ischemia or if there was objective evidence of myocardial ischemia by stress testing. Results: The initial procedure was successful in 149 patients (92.5%) in the DES arm. There were no statistically significant major in-hospital complications in the DES group, compared to BMS group which showed 4 cases of in-hospital deaths (p = 0.017). At Twelve months ± 3 months follow-up, MACE were significantly less frequent in the DES group compared to the BMS group, including death (0.8% vs. 6.4%, p = 0.004) and need for CABG (1.7% vs. 10%, p = 0.012). Conclusions: The main finding of our study is that, compared to the BMS, implantation of the DES in coronary ostial lesions appears safe and effective. It is associated with high procedural success rate, low immediate and in-hospital complication rate, infrequent late adverse events and favourable long-term clinical and angiographic outcomes compared with bare metal stents implantation at 12-month follow-up. Advanced age, previous myocardial infarction and acute coronary syndromes at presentation were all found to be independent positive predictors for clinical events after drug eluting stent implantation in ostial lesions.

Successful stent-in-stent dilatation of the common bile duct through a duodenal prosthesis,a novel technique for malignant obstruction:A case report and review of literature

For patients suffering from both biliary and duodenal obstruction,endoscopic retrograde cholangiopancreatography(ERCP) with stent placement is the treatment of choice.ERCP through an already existing duodenal prosthesis is an uncommon procedure and furthermore no studies have reported installing a covered metal stent onto an already existing bare metal stent in the common bile duct(CBD).We describe a rare case of a stent-in-stent dilatation of the CBD through an already existing self-expanding metal stent in the second part of duodenum for the patient presenting with jaundice in setting of biliary and duodenal obstruction from pancreatic adenocarcinoma.The biliary obstruction was relieved with a decrease in bilirubin levels post-stenting.

药物洗脱支架与金属裸支架治疗椎动脉开口狭窄的疗效

目的探讨药物洗脱支架与金属裸支架治疗椎动脉开口狭窄的疗效。方法收集2015年6月至2021年6月青岛大学附属医院收治的230例椎动脉开口动脉粥样硬化狭窄患者的临床资料,按照椎动脉植入支架的不同将其分为药物洗脱支架组(n=121)和金属裸支架组(n=109)。比较两组患者术前狭窄程度、术后即刻血管残余狭窄程度、术后6个月改良Rankin量表(mRS)评分、术后6个月美国国立卫生研究院卒中量表(NIHSS)评分、围手术期并发症、术后至出院前时间、出院时卒中或死亡发生情况。观察两组患者术后支架内再狭窄情况、卒中或短暂性脑缺血发作(TIA)发生情况。结果术后即刻,两组患者血管残余狭窄程度均低于本组术前,差异均有统计学意义(P﹤0.05)。术后6个月,两组患者NIHSS评分、mRS评分均低于本组术前,差异有统计学意义(P﹤0.05)。两组患者均未发生围手术期并发症,术后至出院前时间、出院时卒中或死亡发生率比较,差异均无统计学意义(P﹥0.05)。术后1、6个月,两组患者卒中或TIA发生率比较,差异均无统计学意义(P﹥0.05)。术后12个月,药物洗脱支架组患者再狭窄率为7.55%(8/106),低于金属裸支架组患者的23.53%(24/102),差异有统计学意义(P﹤0.05)。结论药物洗脱支架与金属裸支架治疗椎动脉开口狭窄均安全、有效,可有效改善患者神经功能与日常生活能力,且药物洗脱支架效果更好,可有效降低术后远期支架内再狭窄率、卒中或病死率。

支架植入治疗血液透析相关中心静脉病变效果及影响通畅率的因素

目的 探讨支架植入治疗血液透析(血透)相关中心静脉病变(CVD)的效果,分析影响通畅率的因素。方法 纳入2015年12月至2020年3月重庆医科大学附属第一医院金山医院收治的因血透相关CVD接受腔内支架植入术患者,收集一般资料、手术信息、术后随访情况,分析影响通畅率的因素。结果 共纳入89例患者,根据支架类型分为覆膜支架组(n=70)和裸支架组(n=19),覆膜支架又分为Viabahn(n=17)和Fluency(n=53)。术后3、6、12、24个月初级通畅率和次级通畅率在覆膜支架组分别为97.1%、88.6%、71.4%、55.7%和100%、98.6%、94.3%、85.7%,裸支架组分别为84.2%、57.9%、21.1%、15.8%和100%、100%、84.2%、47.4%,两组间比较差异均有统计学意义(均P<0.01)。Viabahn支架初级通畅率优于Fluency支架(P=0.044),次级通畅率差异无统计学意义(P=0.061)。多因素分析显示,覆膜支架长度与初级通畅率相关(OR=2.162,95%CI=1.248~5.764,P=0.048),支架长度越长初次通畅率越低。结论 支架植入治疗血透相关CVD安全有效。覆膜支架通畅率优于裸支架,Viabahn通畅率优于Fluency。支架长度是影响覆膜支架通畅率的危险因素。

裸金属支架与药物洗脱支架在经皮冠状动脉介入术治疗中的研究现状

经皮冠状动脉介入术(PCI)是一种有利于解除冠状动脉狭窄、改善心肌供血的治疗手段。随着介入材料的发展,裸金属支架(BMS)和药物洗脱支架(DES)在临床中已被广泛使用,患者术后的支架内再狭窄(ISR)、靶血管血运重建(TVR)、支架内血栓(IST)以及主要心血管不良事件(MACE)的发生率已成为研究的热点。本文就BMS和DES应用于PCI治疗的研究现状作一综述,以期为临床选择介入材料提供有益的指导。

药物涂层球囊、Viabahn覆膜支架及金属裸支架治疗下肢动脉硬化闭塞症的效果比较

目的 比较药物涂层球囊(DCB)、Viabahn覆膜支架及金属裸支架(BMS)治疗下肢动脉硬化闭塞症(ASO)的效果。方法 选取2017年7月至2019年12月在温岭市第一人民医院治疗的下肢ASO患者104例,按照治疗方法的不同分为DCB组37例、Viabahn组34例和BMS组33例。比较各组通畅率、踝肱指数(ABI)以及不良事件发生情况。结果 术后3、6个月3组患者通畅率比较,差异均有统计学意义(P<0.05),且DCB组(78.38%、86.49%)、Viabahn组(76.47%、85.29%)通畅率明显高于BMS组(51.52%、60.61%)(P<0.05)。术后3、6、9、12个月3组患者ABI均明显升高(P<0.05),3组患者间歇性跛行距离比较,差异均无统计学意义(均P>0.05)。3组患者均未出现肢体截肢、心脑血管事件以及死亡等严重不良事件。结论 与BMS相比,DCB和Viabahn覆膜支架治疗下肢ASO可更明显改善ABI,提高通畅率,且安全性相当。

单层或双层裸金属支架治疗冠状动脉瘤的流体力学分析

目的:使用计算流体力学研究单层或双层裸金属支架治疗冠状动脉瘤(冠脉瘤)的新方法。方法:选取5例瘤体直径不同的冠脉瘤患者,分别置入单层或双层裸金属支架治疗,使用计算流体力学方法构建冠脉瘤模型并模拟单、双层裸金属支架置入过程,分析裸金属支架置入后冠脉瘤内血液动力学参数的变化。结果:在模型1(病例1,瘤体直径4 mm)中,相比无支架状态和双层裸金属支架状态,单层裸金属支架状态时血流速度最低。在模型2至模型5(病例2~病例5)中(瘤体直径6.5~16.0 mm),相比无支架状态和单层裸金属支架状态,双层裸金属支架状态的血流速度最低。在模型1和模型2中,随着裸金属支架依次模拟置入,冠脉瘤壁面压力和切应力呈现出下降趋势。模型3、4和5则表现出随着裸金属支架的依次模拟置入,冠脉瘤壁面压力逐渐上升,切应力则呈现出个体化变化。随访发现5例冠脉瘤均成功封闭且无明显支架内再狭窄。结论:瘤体直径<6.5 mm的冠脉瘤可采用单层裸金属支架覆盖瘤颈,瘤体直径在6.5~16.0 mm之间的冠脉瘤建议采用双层裸金属支架覆盖瘤颈。该技术可有效改变冠脉瘤内血流速度及载瘤动脉血流导向,促进瘤体愈合。

球囊预扩张联合药物洗脱支架治疗椎动脉起始部狭窄患者的疗效观察

目的探讨球囊预扩张联合药物洗脱支架治疗椎动脉起始部狭窄患者的安全性和有效性。方法收集2015年1月至2018年12月在台州市第一人民医院行椎动脉起始部支架置入术的患者152例,随访1年,失访6例,根据置入支架的种类分为药物洗脱支架组48例和金属裸支架组98例,比较两组患者的一般资料、随访期内两组的新发症状和支架内再狭窄率。根据有无支架内再狭窄分为再狭窄组和无再狭窄组,比较两组患者的新发症状。结果药物洗脱支架组患者年龄比金属裸支架组更小(t=2.170,P<0.05);1年随访期内药物洗脱支架组比金属裸支架组的支架内再狭窄率及新发症状更低,差异有统计学意义(χ^(2)=4.435、5.204,P<0.05);2年随访期内药物洗脱支架组比金属裸支架组的支架内再狭窄率及新发症状均更低,差异有统计学意义(χ^(2)=4.345、6.062,P<0.05);与无再狭窄患者比较,支架内再狭窄患者在1年随访期内和2年随访期内均出现更多新发症状病例,差异有统计学意义(χ^(2)=13.042、14.368,P<0.01)。结论球囊预扩张联合药物洗脱支架比金属裸支架治疗椎动脉起始部狭窄,支架内再狭窄率更低,新发症状更少。

药物球囊预扩张联合裸金属支架治疗椎动脉起始部狭窄的效果

目的观察药物球囊预扩张联合裸金属支架治疗椎动脉起始部狭窄的效果。方法选取2018-08—2021-07沧州市人民医院收治的104例椎动脉起始部狭窄患者为研究对象,采用随机数字表法分为研究组(给予药物球囊预扩张联合裸金属支架置入,52例)和对照组(给予普通球囊扩张支架置入,52例)。对比2组患者手术成功率及手术前后血管狭窄率,以及手术前后神经功能改善情况。随访1 a,对比2组患者血管内再狭窄发生情况及围手术期并发症发生率。结果研究组手术成功率(98.08%)与对照组(96.15%)比较差异无统计学意义(χ^(2)=0.343,P=0.558);研究组术后6、12个月血管狭窄率分别为(12.43±3.18)%、(13.61±3.25)%,显著低于对照组的(13.78±3.62)%、(15.26±4.78)%(t=2.020、2.058,P=0.046、0.042)。研究组术后1、3、6、12个月美国国立卫生研究院卒中量表(NIHSS)评分分别为(2.14±0.59)分、(1.93±0.47)分、(1.75±0.43)分、(1.48±0.32)分,显著低于对照组的(2.51±0.73)分、(2.23±0.68)分、(2.01±0.40)分、(1.84±0.46)分(t=2.843、2.617、3.192、4.633,P=0.005、0.010、0.002、<0.001)。术后6、12个月研究组血管内再狭窄发生率(5.77%、9.62%)均显著低于对照组(19.23%、26.92%,χ^(2)=4.308、5.216,P=0.038、0.022)。研究组并发症发生率(5.77%)与对照组(13.46%)比较差异无统计学意义(χ^(2)=1.770,P=0.183)。结论采用药物涂层球囊预扩张联合裸金属支架置入的方法治疗椎动脉起始部狭窄,在保证手术成功率、安全性、有效性的前提下,可有效减小血管狭窄率、改善神经功能、降低再狭窄发生率。

Viabahn覆膜支架在主髂动脉闭塞中的应用效果分析

目的比较分析主髂动脉闭塞手术中裸支架、Viabahn覆膜支架应用对踝肱指数改善的差异。方法选取2018年3月—2020年3月巨野县人民医院确诊的68例主髂动脉闭塞患者行回顾性研究,以患者治疗中血管内支架类型差异分为对照组(35例,裸支架)、观察组(33例,Viabahn覆膜支架)。观察两组患者踝肱指数、Fontaine分期、并发症发生率以及通畅率等情况。结果两组术后3 d间歇性跛行距离[观察组(512.06±89.24)m,对照组(486.48±52.65)m]与术前相比均明显上升,差异有统计学意义(t=22.559、31.819,P<0.05)。术后两组间歇性跛行距离、手术并发症发生率比较,差异无统计学意义(P>0.05)。观察组术后3、6个月的踝肱指数和对照组水平对比,差异无统计学意义(P>0.05);术后12、24个月的踝肱指数高于对照组,差异有统计学意义(P<0.05)。两组一期通畅率、TASCⅡ分型通畅率、保肢率和事件阳性率比较,差异无统计学意义(P>0.05),观察组TLR率低于对照组,差异有统计学意义(P<0.05)。结论Viabahn覆膜支架在主髂动脉闭塞的治疗中获得了较好的应用效果,可保持较好的短中期通畅率,且再次手术干预率相对较低,值得临床应用和推广。

Silverhawk斑块旋切结合国产紫杉醇药物涂层球囊与金属裸支架治疗下肢动脉闭塞的疗效分析

目的探讨Silverhawk斑块旋切、国产紫杉醇药物涂层球囊(DCB)和金属裸支架治疗下肢动脉闭塞的临床疗效。方法前瞻性选取2019年1月~2021年12月我院收治的下肢动脉闭塞病人101例,按照随机对照法将其分为两组,A组进行Silverhawk斑块旋切治疗,B组在A组基础上加以国产紫杉醇DCB+金属裸支架治疗,对两组的临床指标、临床驱动靶病变再次血运重建率、内皮素(ET)-1、一氧化氮(NO)以及血浆P选择素水平进行比较。结果B组病人治疗后的临床指标优于A组,治疗后12小时两组病人的血浆P选择素、ET-1水平降低,治疗后12小时两组病人的NO水平上升,且治疗后B组病人的血浆P选择素、ET-1及NO水平均优于A组,B组病人术后6个月、12个月的再次血运重建率均低于A组,差异均有统计学意义(P<0.05)。结论应用Silverhawk斑块旋切+国产紫杉醇DCB+金属裸支架治疗下肢动脉闭塞的临床疗效显著,改善病人的血管通畅率、ET-1、NO以及血浆P选择素水平,提高其踝肱指数,降低靶病变血流重建率。

药物洗脱支架植入术联合氯吡格雷治疗冠心病的临床疗效

目的探讨药物洗脱支架(DES)植入术联合氯吡格雷治疗冠心病的临床疗效。方法回顾性分析2007年1月至2011年12月,该院收治的73例接受经皮冠状动脉介入治疗(PCI)的患者,对照组(DES治疗术后,除了常规二级预防以外,服用氯吡格雷12个月)28例,观察组(DES治疗术后,除了常规二级预防外,服用氯吡格雷18个月)45例。比较两组治疗2年后急性心血管事件的再发生率、再次住院率、死亡率的差别。结果对照组与观察急性心血管事件发生率(10.7%vs 4.4%,P=0.001)、再次住院率(14.3%vs 4.4%,P=0.001)、晚期血栓发生率(14.3%vs 6.3%,P=0.001)比较差异显著,有统计学意义;死亡率(0%vs 0%,P=0.95)比较差异无统计学意义(P>0.05)。两组患者治疗后血液流变学指标显著优于治疗前,差异有统计学意义(P<0.05);观察组治疗后血液流变学指标明显优于对照组,差异有统计学意义(P<0.05)。远期观察疗效良好。结论 DES植入联合氯吡格雷对冠心病治疗效果良好,值得推广。

冠心病合并糖尿病患者置入药物洗脱支架和裸金属支架2年临床观察

目的:评价冠心病合并糖尿病患者成功置入药物洗脱支架(DES)和裸金属支架(BMS)2年后的有效性和安全性。方法:本研究入选了2004-04至2006-10在我院行择期支架置入术的冠心病合并糖尿病患者1565例。入选患者分为DES组(n=1317)和BMS组(n=248例)。随访资料包括术后30天、1年和2年的死亡、心肌梗死、血栓、靶病变血运重建和靶血管血运重建。本研究比较了DES和BMS两组间各种临床事件累积发生率的差异,同时通过倾向性评分调整后的Cox比例风险模型比较两组术后2年的临床随访结果。结果:DES和BMS两组患者术后2年出现学术研究联合会(ARC)定义的支架内血栓形成率差异无统计学意义,但DES组术后30天明确血栓形成率显著低于BMS组(0.08%比0.81%,P=0.016)。术后2年与BMS相比,DES组靶病变血运重建率[3.88%比10.89%;风险比0.159(95%可信区间:0.151～0.444),P<0.0001]和靶血管血运重建率[5.48%比11.69%;风险比0.383(95%可信区间:0.232～0.633),P<0.0001]的风险均显著降低,差异均有统计学意义。两组间全因死亡率、心肌梗死发生率及全因死亡/心肌梗死发生率差异均无统计学意义。结论:对于冠心病合并糖尿病患者而言,与置入BMS相比,使用DES可以显著降低靶病变血运重建率和靶血管血运重建率,但是全因死亡率、心肌梗死发生率和血栓形成率的差异均无统计学意义。